CSIMarket
 


Axcella Health Inc   (AXLA)
Other Ticker:  
 

Axcella Health Inc 's Working Capital Ratio

AXLA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




AXLA Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 185.03 % 30.28 % 9.71 % 30.4 % 46.89 %
Y / Y Current Assets Change -59.76 % -42.51 % -31.67 % -48.04 % -43.46 %
Working Capital Ratio MRQ 1.23 2.94 5.58 5.58 8.72
Overall Ranking # # # # #
Seq. Current Liabilities Change 41.03 % 36.43 % 13.22 % 30.85 % -35.54 %
Seq. Current Assets Change -40.99 % -28.1 % 13.3 % -16.29 % -15.69 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 1.23 above Axcella Health Inc average.

Within Biotechnology & Pharmaceuticals industry Axcella Health Inc booked the highest Working Capital Ratio than Axcella Health Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is AXLA most successful ?
Working Capital Ratio AXLA on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Axcella Health Inc 's Current Liabilities $ 22 Millions Visit AXLA's Balance sheet
Axcella Health Inc 's Current Assets $ 27 Millions Visit AXLA's Balance sheet
Source of AXLA's Sales Visit AXLA's Sales by Geography


Cumulative Axcella Health Inc 's Working Capital Ratio

AXLA's Working Capital Ratio for the trailling 12 Months

AXLA Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 185.03 % 30.28 % 9.71 % 30.4 % 46.89 %
Y / Y Current Assets TTM Growth -59.76 % -42.51 % -31.67 % -48.04 % -43.46 %
Working Capital Ratio TTM 3.27 5.21 6.49 7.39 9.22
Total Ranking TTM # 563 # 1031 # 889 # 768 # 707
Seq. Current Liabilities TTM Growth 41.03 % 36.43 % 13.22 % 30.85 % -35.54 %
Seq. Current Assets TTM Growth -40.99 % -28.1 % 13.3 % -16.29 % -15.69 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to jump in Current Liabilities in the III. Quarter to $22.11 millions, average cumulative Working Capital Ratio decreased to 3.27 below the Axcella Health Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 80 other companies have achieved higher Working Capital Ratio than Axcella Health Inc . While overall ranking remained unchanged compare to previous quarter at no. 563.

Explain Working Capital Ratio
Where is AXLA most successful ?
Working Capital Ratio AXLA on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 81
Healthcare Sector # 307
Within the Market # 563


TTM Working Capital Ratio Statistics
High Average Low
13.82 10.12 3.11
(Dec 31 2020)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Greenlight Biosciences Holdings Pbc  3.37 $ 109.307  Millions$ 32.416  Millions
Oyster Point Pharma Inc   3.35 $ 97.707  Millions$ 29.197  Millions
Aspira Women s Health Inc   3.18 $ 22.976  Millions$ 7.224  Millions
Denali Therapeutics Inc   3.16 $ 1,138.526  Millions$ 360.670  Millions
Avanos Medical Inc   3.16 $ 470.000  Millions$ 148.900  Millions
X4 Pharmaceuticals Inc  3.11 $ 85.718  Millions$ 27.549  Millions
Educational Development Corporation  3.09 $ 70.221  Millions$ 22.715  Millions
Achieve Life Sciences Inc   3.03 $ 20.957  Millions$ 6.916  Millions
Lineage Cell Therapeutics Inc   3.01 $ 68.509  Millions$ 22.739  Millions
Cue Health Inc   2.97 $ 521.872  Millions$ 175.462  Millions
Nanovibronix Inc  2.96 $ 4.989  Millions$ 1.687  Millions
Coherent Corp   2.87 $ 3,394.630  Millions$ 1,183.084  Millions
Windtree Therapeutics Inc  2.84 $ 10.032  Millions$ 3.535  Millions
Oncocyte Corporation  2.83 $ 36.636  Millions$ 12.952  Millions
Gamida Cell Ltd   2.76 $ 62.703  Millions$ 22.713  Millions
Sangamo Therapeutics Inc   2.75 $ 336.621  Millions$ 122.361  Millions
Myomo Inc   2.69 $ 11.052  Millions$ 4.114  Millions
Coherus Biosciences inc   2.62 $ 448.275  Millions$ 171.319  Millions
Pactiv Evergreen Inc   2.58 $ 2,368.000  Millions$ 918.000  Millions
Cadre Holdings inc   2.53 $ 187.813  Millions$ 74.371  Millions
Biogen Inc   2.49 $ 9,765.800  Millions$ 3,926.400  Millions
Neurocrine Biosciences Inc   2.49 $ 1,205.500  Millions$ 485.100  Millions
Msa Safety Inc  2.47 $ 862.100  Millions$ 349.138  Millions
Myriad Genetics Inc   2.47 $ 352.300  Millions$ 142.800  Millions
Harvard Bioscience Inc  2.43 $ 51.818  Millions$ 21.360  Millions
Repligen Corp  2.40 $ 953.233  Millions$ 397.540  Millions
Bruker Corporation  2.36 $ 2,036.600  Millions$ 864.600  Millions
Ayala Pharmaceuticals Inc   2.28 $ 13.032  Millions$ 5.705  Millions
Aerie Pharmaceuticals Inc   2.27 $ 302.813  Millions$ 133.333  Millions
Steris Plc  2.25 $ 1,888.299  Millions$ 838.847  Millions

Date modified: 2022-11-02T15:14:20+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

IOAC's Profile

Stock Price

IOAC's Financials

Business Description

Fundamentals

Charts & Quotes

IOAC's News

Suppliers

IOAC's Competitors

Customers & Markets

Economic Indicators

IOAC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071